Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 26;161(4):416-420.
doi: 10.1001/jamadermatol.2024.6567. Online ahead of print.

Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis

April W Armstrong  1 , Kathryn Lee  2 , Danielle Yee  1 , Michael Woodbury  3 , Melissa Zundell  4 , Caterina Zagona-Prizio  5 , Jenna Yousif  4 , Carly Grant  3 , Ali Shields  3 , Peichi Chou  6 , Kristina Callis Duffin  7 , Alice B Gottlieb  4 , Joseph F Merola  8 , Lourdes Perez-Chada  3
Affiliations

Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis

April W Armstrong et al. JAMA Dermatol. .

Abstract

Importance: A critical need exists for developing a validated dermatologic-specific treatment satisfaction instrument.

Objective: To evaluate the structural validity, internal consistency, construct validity, and test-retest reliability of the 7-item dermatology-specific treatment satisfaction (DermSat-7) instrument in patients with psoriasis.

Design, setting, and participants: This survey study was conducted from July 2020 to April 2023 in dermatology outpatient clinics at the University of Southern California, Brigham and Women's Hospital, and Mount Sinai Union Square and included adults (aged ≥18 years) with psoriasis who were fluent in English. On day 1, the clinician at the study sites assessed psoriasis disease severity in person using the Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Physician Global Assessment (PGA). On day 1, study participants completed the DermSat-7, the generic 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), and the Dermatology Life Quality Index (DLQI). They also answered demographic questions and reported their own disease severity using the Patient Global Assessment (PtGA). On day 14 (±2 days), the patient then completed the DermSat-7 and PtGA a second time.

Main outcomes and measures: The DermSat-7 is a 7-item self-administered instrument with a recall period of 14 days that assesses patient satisfaction with their treatments across various inflammatory dermatology diseases, including psoriasis. Construct validity, structural validity, internal consistency, and test-retest reliability of DermSat-7 were assessed as defined by the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) taxonomy and reported following the COSMIN reporting guideline for studies on measurement properties.

Results: The analysis included 142 patients with psoriasis (mean [SD] age, 51.1 [15.5] years; 77 males [54.2%]). Exploratory factor analysis and confirmatory factor analysis supported the unidimensionality of the DermSat-7 domains. The internal consistency of the effectiveness and convenience domains was high with a Cronbach α of 0.88 and 0.81, respectively. Regarding construct validity, differences between groups based on PASI/PGA scores were aligned with preexisting hypotheses, and the correlations between DermSat-7 and TSQM-9 subscores were strong to very strong (ρ = 0.75 for effectiveness; ρ = 0.66 for convenience; and ρ = 0.70 for overall satisfaction; all P < .001). Intraclass correlation was 0.85, indicating high test-retest reliability.

Conclusions and relevance: This survey study found that the DermSat-7 may be a valid and reliable instrument for measuring treatment satisfaction in patients with psoriasis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Armstrong reported receiving grants from AbbVie; ASLAN; BMS; Dermavant Sciences; Dermira; Eli Lilly; Galderma; Incyte; Janssen; Leo Pharma; Meiji Seika Pharma Co; Modernizing Medicine; Nimbus Therapeutics; Novartis; Ortho Dermatologics; Pfizer; Sanofi Genzyme; UCB; Ventyx Biosciences, personal fees from AbbVie; ASLAN; Almirall; Amgen; Arcutis; Beiersdorf; BMS; Dermavant; EPI Health; Eli Lilly; Galderma; Janssen; LEO Pharma; Mindera; Nimbus; Organon & Co; Sanofi; Sun Pharma; Takeda; Ventyx Biosciences; Regeneron; UCB; Incyte, and other from Boehringer Ingelheim; Parexel Data Safety Monitoring Board outside the submitted work. Dr Callis Duffin reported receiving grants from Boehringer-Ingelheim, personal fees from Boehringer-Ingelheim and AbbVie, grants from Amgen, personal fees from Amgen, grants from Pfizer, personal fees from Pfizer, Novartis, Bristol-Myers Squibb, and Janssen, grants from UCB, personal fees from UCB, grants from Corevitas, and personal fees from Corevitas and Lilly outside the submitted work. Dr Gottlieb reported receiving grants from UCB paid to Mt Sinai, personal fees from UCB, grants from Janssen paid to Mt Sinai, personal fees from Janssen, grants from Moonlake, grants from BMS paid to Mt Sinai, personal fees from BMS, Highlights, Boehringer Ingelheim, Novartis, and Lilly, grants from Highlight paid to Mt Sinai, and personal fees from Sanofi during the conduct of the study. Dr Merola reported receiving personal fees from AbbVie, Amgen, and AstraZeneca, grants from Biogen, personal fees from Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Janssen, Lilly, Moonlake, and Novartis, grants from Pfizer, personal fees from Sanofi Regeneron, grants from Sun Pharma, and personal fees from UCB outside the submitted work. Dr Perez-Chada reported receiving grants from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis outside the submitted work. No other disclosures were reported.

References

    1. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940-946. doi:10.1001/jamadermatol.2021.2007 - DOI - PMC - PubMed
    1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi:10.1136/bmj.m1590 - DOI - PMC - PubMed
    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006 - DOI - PubMed
    1. Murage MJ, Tongbram V, Feldman SR, et al. . Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483-1503. doi:10.2147/PPA.S167508 - DOI - PMC - PubMed
    1. Salame N, Perez-Chada LM, Singh S, et al. . Are your patients satisfied a systematic review of treatment satisfaction measures in psoriasis. Dermatology. 2018;234(5-6):157-165. doi:10.1159/000490413 - DOI - PubMed

LinkOut - more resources